This randomized clinical trial investigates whether carotuximab plus pazopanib improves progression-free survival vs pazopanib alone in adult patients with advanced angiosarcoma.

No abstract

No abstract

No abstract

The combination of carotuximab with axitinib did not provide a benefit over axitinib monotherapy in patients with metastatic clear cell renal cell carcinoma who had previously progressed on one or more VEGFtargeted therapies.• Exploratory evaluation of pre-treatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels.